Biomedical Tax Incentive Bill Allows Firms To Retain Credits After Equity Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
Pending legislation creating tax incentives for the biomedical industry would spur innovation, Rep. Anna Eshoo (D-Calif.) said at the California Healthcare Institute Policy Forum at Stanford University
You may also be interested in...
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability